Covid-19 Vaccine Shipper & Logger Returns

Listed below are a range of educational instructions and materials to support the COVID-19 Vaccine Shipper and Logger Return process. The illustrations, instructions, and videos below outline the process for returning thermal shippers equipped with Controlant temperature loggers. For any questions, please reach out to logistics@controlant.com.

Logger and Box Return Process

Express or Indi­vidual Returns*

Process flow diagram illustrating Controlant’s shipment monitoring stages, from initiation to completion. Shows each step in the journey of pharmaceutical shipments, highlighting key checkpoints for temperature and compliance tracking.

1. Confirm Receipt of Return Label
Each shipment includes a blank label inside the Thermal Shipper. Shipments performed by an express carrier (i.e., DHL Express; UPS Small Parcel; FedEx) will include a return label (airway bill).

2. Prepare Foldable Box
Gently remove the foldable box from the Thermal Shipper. In preparation for return shipment, prepare the foldable box.

3. Remove Controlant Logger & Probe
Carefully remove the logger and probe from the Thermal Shipper. Ensure the probe and modem is neither disconnected nor damaged in process.

4. Secure Controlant Logger & Probe
Place the logger inside the bubble bag. Seal box closed and place box in your daily express pickup area.

5. Arrange for Pickups
If you do not have regular carrier (i.e, FedEx; DHL; UPS) pickups, click the link in the Controlant delivery confirmation email (includes the Quality Disposition report) to request a pick-up.

6. Box(es) Picked Up
Return box(es) containing the logger should be readily accessible for the carrier at the prearranged time of pickup.

Logger Return Box Preparation

1. Confirm Receipt of Foldable Return Box
After having received a shipment, confirm receipt of foldable box (located on inner flap, as displayed in graphic below) with preprinted return label attached to it.

Note:
If you have not received a shipment delivery email from Controlant, please contact pfizer.logistics@controlant.com for further guidance.

In case of a missing foldable box, request a new one via the link in the delivery confirmation email received from Controlant.

2. Prepare Return Box for Device
To return the Controlant logger, please detach and utilize the pre-labeled foldable return box located on the inner flap of the thermal shipping container.

Note:
If foldable return box is missing, lost, damaged or the pre-attached label is non-scannable, please utilize the “Request a New Return Box” link in the shipment delivery confirmation email received from Controlant.

3. Transport Logger into Return Box
Carefully remove the logger and probe from the thermal shipper as to not disconnect or damage the fragile probe.

4. Package Logger Safely
Place the Temperature Monitoring Device and probe inside the bubble bag and carefully insert into the foldable return box.

5. Arrange Pickup
Place return box in your daily express pickup area. If you do not have regular daily carrier pickups (i.e., UPS FedEx; DHL), open the delivery confirmation email received from Controlant and click on “Please confirm collection or usage” to inform Controlant that the box is ready for collection. A popup screen will generate; click the “Yes, they are ready to be collected” option. Controlant will automatically receive a notification and arrange the pickup with the carrier.

6. Return Completion
Pick up of box(es) by the carrier. Box(es) should be readily available and accessible for the carrier at the prearranged time of pickup.

Instructional illustration showing the unpacking, setup, and activation steps for a Controlant monitoring device, along with final confirmation steps on a digital interface. Provides a visual guide for users in preparing and confirming the device for shipment monitoring.

Safe Handling Guidelines for Dry Ice

Facts About Dry Ice
Dry ice is the frozen form of carbon dioxide. When heated, most frozen solids melt to a liquid form, but dry ice transforms directly into a gas (sublimation). Dry ice sublimes at temperatures at or above -109°F (-80°C). The main hazards of dry ice include asphyxiation and burns. Use of dry ice in confined spaces (small rooms or walk-in coolers) and/or poorly ventilated areas can result in depletion of oxygen resulting in asphyxiation. Exposed skin should be protected from contact with dry ice. To ensure appropriate controls are in place, review the enclosed Safety Data Sheet (SDS) and consult with your EHS/Occupational Health department.

Ventilation
At room temperature (including most cold storage temperatures), dry ice becomes carbon dioxide vapor which may cause difficulty breathing or suffocation. If dry ice has been in a closed area, trailer or container for more than 10 minutes, open doors and allow adequate ventilation before entering. Leave area containing dry ice if you start to pant and breath quickly, develop a headache, notice that your fingernails or lips start to turn blue, or experience other symptoms of asphyxiation. These signs can indicate that you have inhaled too much carbon dioxide. Carbon dioxide is heavier than air and accumulates in low, poorly ventilated spaces.

Burn Treatment
Dry ice may cause cold burns to the skin. Seek medical care as directed by the Dry Ice Safety Data Sheet.

Disposal
Once dry ice is no longer needed, open the container and leave it at room temperature in a well-ventilated area. It will readily sublime from a solid to a gas. DO NOT leave dry ice in an unsecured area. DO NOT place in drain or flush in toilet. DO NOT dispose in trash.

Infographic outlining key safety measures for dry ice handling, including avoiding touch and eye contact, not ingesting, keeping in ventilated spaces, and avoiding airtight containers. Guidelines is critical for safe, compliant use in pharmaceutical logistics.


The Controlant POU Email Communications are adopting new formats to include enhanced versioning and design starting in Q3 2022. The illustrations and design are subject to change based on your market and shipment details.

For additional Pfizer training materials, please visit your market’s health care professional (HCP) website. Once a market receives regulatory authorization by their respective location, they can visit the market-specific instance of cvdvaccine.com or comirnatyglobal.com for more Healthcare Professional (HCP) specific information and support.

Alternatively, you can also visit the Pfizer BioNTech Global Readiness Website for additional COVID-19 readiness materials containing information for properly distributing and storing the vaccine to anticipated vaccination sites.